Novartis Korea assigned Zelmac promotion to Uthis.

Published: 2007-01-26 06:59:00

Updated: 2007-01-26 06:59:00

Novartis Korea announced to assign a product detailing activity of Zelmac (tegacerod) sales promotion in local private clinic markets under a certain agreement with Uthis company, a specialized out-sourcing company in Korea. Zelmac is a drug approved for the treatment of irritable colon syndrome ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK